SpagoPix product patent approved in Japan
Spago Nanomedical announce today that the Japanese patent authorities has decided to approve the company´s patent application comprising the nanoparticles that are the foundation of the SpagoPix project.
The approved patent (Manganese comprising nanostructures, 2014-531227) means that Spago Nanomedical gains strategic market protection for SpagoPix on the world´s third largest market for MRI contrast agents. The patent include the company´s unique nanoparticles which will now gain market exclusivity in Japan until at least 2032.
The application for product protection is submitted in all substantial markets and patent has previously been granted in e.g. USA.
Late 2016 the product candidate SN132D was appointed in the SpagoPix project and production of material for regulatory tox- and safety studies is underway. The aim is work with a well-established CRO for initiation of the program as soon as possible.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, email@example.com.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.
The aim of SpagoPix is to improve cancer diagnostics using magnetic resonance imaging (MRI) by facilitating early discovery of tumors and metastases. Early discovery improves the chances of efficient treatment and survival of cancer patients. Tumorad® is a further development of the company´s proprietary nanoparticles with the purpose of delivering radionuclides for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer.
The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 25 January, 2017.
For further information, see www.spagonanomedical.se.